MedTrace Logo

A Multicenter, Clinical Study of FOLFOXIRI With Bevacizumab As First-line Therapy in Patients With mCRC

NCT02246049 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 69

Last updated 2017-06-19

No results posted yet for this study

Summary

The purpose of this study to assess efficacy and tolerability of combination therapy FOLFOXIRI with Bevacizumab (BV) as a first-line therapy in patients with metastatic colorectal cancer.

Conditions

  • Colorectal Neoplasms

Interventions

BIOLOGICAL

Bevacizumab

Given IV

DRUG

5-fluorouracil

Given IV

DRUG

Irinotecan hydrochloride

Given IV

DRUG

Leucovorin calcium

Given IV

DRUG

Oxaliplatin

Given IV

Sponsors & Collaborators

  • EPS Corporation

    lead OTHER

Principal Investigators

  • Takeshi Kato, M.D., Ph.D · Department of Surgery, National Hospital Organization Osaka National Hospital.

  • Akiyoshi Kanazawa, M.D., Ph.D · Department of Surgery, Shimane Prefectural Central Hospital.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-05-31
Primary Completion
2017-02-28
Completion
2017-02-28

Countries

  • Japan

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02246049 on ClinicalTrials.gov